SCHEMBL3928697

SCHEMBL3928697

CC(Cc1ccc(N2CC(=O)NS2(=O)=O)c(OCc2ccccc2)c1)C(=O)c1ccccc1.[KH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 8/20 0.41
PTPN2 P17706 1/20 0.38
ADAM17 P78536 2/20 0.36
MMP9 P14780 1/20 0.36
PTGER1 P34995 2/20 0.36
PTGER4 P35408 2/20 0.36
PTGER3 P43115 2/20 0.36
PTGER2 P43116 2/20 0.36
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GLRA1 P23415 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ATM Q13315 1/20 0.33
MMP1 P03956 1/20 0.33
CSF1R P07333 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SMPD1 P17405 1/20 0.33
HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3917093 0.99 PTPN1 (0.42) PTPN1PTPN2ADAM17MMP9PTGER1
Potassium SCHEMBL3929625 0.98 PTPN1 (0.41) PTPN1PTPN2ADAM17MMP9PTGER1
SCHEMBL3930874 0.90 PTPN1 (0.40) PTPN1PTPN2ADAM17MMP9ALDH1A1
SCHEMBL4320108 0.89 PTPN1 (0.41) PTPN1PTPN2ADAM17MMP9PTGER1
SCHEMBL3918219 0.89 PTPN1 (0.40) PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2
SCHEMBL3926366 0.89 PTPN1 (0.41) PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2
Potassium SCHEMBL3930878 0.89 PTPN1 (0.41) PTPN1PTPN2ALDH1A1MAPTSMN1; SMN2
SCHEMBL3915830 0.88 PTPN1 (0.42) PTPN1PTPN2ADAM17MMP9PTGER1
Potassium SCHEMBL4320111 0.88 PTPN1 (0.41) PTPN1PTPN2ADAM17MMP9PTGER1
SCHEMBL2937456 0.84 PTPN1 (0.48) PTPN1PTPN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC PTPN1 21/4885PTPN2 5/4885ADAM17 3560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.